Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
06 juil. 2020 16h04 HE
|
Otonomy, Inc.
OTO-313 demonstrated a higher proportion of responders than placeboGiven clear signal in this proof of concept study, Otonomy plans to advance OTO-313 to full Phase 2 development in tinnitusOTO-313...
Otonomy Provides Update on OTIVIDEX® Program
06 juil. 2020 16h02 HE
|
Otonomy, Inc.
SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an...
Otonomy Provides Update on Clinical Trials and Development Programs
15 juin 2020 16h05 HE
|
Otonomy, Inc.
Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020Results from Phase 1/2 trial of...
Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
11 juin 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
10 juin 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Host Pipeline Program Update Conference Call and Webcast
08 juin 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
12 mai 2020 08h00 HE
|
Otonomy, Inc.
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
07 mai 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
Otonomy Provides Business Update Related to COVID-19 Pandemic
09 avr. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a...
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
27 févr. 2020 16h15 HE
|
Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021 Conference call and webcast today at 4:30...